

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen	
2	Reason for the notification		
a)	Position/status	Executive Vice President, Chief Financial Officer (CFO)	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 315.60	26,246
d)	Aggregated information - Aggregated volume - Price	26,246 shares DKK 8,283,237.60	
e)	Date of the transaction	2026-02-10	
f)	Place of the transaction	JANE STREET NETHERLANDS B.V. (JNSI)	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen	
2	Reason for the notification		
a)	Position/status	Executive Vice President, Chief Financial Officer (CFO)	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 315.70	311
d)	Aggregated information - Aggregated volume - Price	311 shares DKK 98,182.70	
e)	Date of the transaction	2026-02-10	
f)	Place of the transaction	CBOE EUROPE - DXE PERIODIC (NL) (BEUP)	

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Alex Bruce

+45 3444 2613

axeu@novonordisk.com

Christoffer Sho Togo Tullin

+45 3079 1471

cftu@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com